Prudential Financial Inc. grew its holdings in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 21.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 223,260 shares of the company’s stock after acquiring an additional 39,130 shares during the quarter. Prudential Financial Inc.’s holdings in Apellis Pharmaceuticals were worth $2,958,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. State Board of Administration of Florida Retirement System raised its position in shares of Apellis Pharmaceuticals by 15.3% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,467 shares of the company’s stock valued at $164,000 after buying an additional 1,659 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Apellis Pharmaceuticals by 159.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,903 shares of the company’s stock valued at $38,000 after buying an additional 1,785 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Teachers Advisors LLC now owns 72,723 shares of the company’s stock valued at $1,293,000 after buying an additional 3,716 shares in the last quarter. Jennison Associates LLC raised its position in shares of Apellis Pharmaceuticals by 0.8% during the 3rd quarter. Jennison Associates LLC now owns 574,859 shares of the company’s stock valued at $10,221,000 after buying an additional 4,395 shares in the last quarter. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $107,000. Hedge funds and other institutional investors own 53.89% of the company’s stock.

Apellis Pharmaceuticals stock opened at $14.00 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 11.89 and a current ratio of 11.89. Apellis Pharmaceuticals Inc has a 1-year low of $11.45 and a 1-year high of $32.00. The stock has a market capitalization of $884.65 million, a P/E ratio of -3.80 and a beta of 0.37.

In other news, major shareholder Morningside Venture Investment acquired 441,176 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, March 11th. The shares were bought at an average cost of $17.00 per share, with a total value of $7,499,992.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 9.30% of the company’s stock.

Several analysts have recently issued reports on APLS shares. Cantor Fitzgerald restated a “buy” rating and set a $53.00 target price on shares of Apellis Pharmaceuticals in a research report on Thursday, December 20th. Citigroup upped their target price on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, December 6th. B. Riley started coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 8th. They set a “buy” rating and a $40.00 target price on the stock. Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 4th. Finally, JPMorgan Chase & Co. cut shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 target price on the stock. in a research report on Wednesday, January 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $39.33.

TRADEMARK VIOLATION WARNING: “Prudential Financial Inc. Acquires 39,130 Shares of Apellis Pharmaceuticals Inc (APLS)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/prudential-financial-inc-acquires-39130-shares-of-apellis-pharmaceuticals-inc-apls/2897100.html.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Recommended Story: Outstanding Shares

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.